Turning Point Therapeutics Inc. priced a public offering of 4.5 million common shares at $45 apiece.
The San Diego-based clinical-stage precision oncology company is also offering underwriters the option to buy up to an additional 675,000 common shares to cover any overallotments.
Turning Point Therapeutics expects gross proceeds of $202.5 million.
The offering is expected to close Sept. 10.
Goldman Sachs & Co. LLC and SVB Leerink are the joint book-running managers for the offering. Guggenheim Securities and Wedbush PacGrow are acting as lead managers.
